
- 2. The following information is based on my knowledge of West's customary and routine business practices during the time I have been employed.
- 3. West obtains news articles under license from Business Wire for inclusion on Westlaw to permit authorized subscribers to access these articles.
- 4. West includes the text of the news articles on Westlaw as they are received from Business Wire.
- 5. The three articles attached to this affidavit are accurate copies of the articles as they appear on Westlaw as of today's date.
- 6. These three articles, to the best of my knowledge and belief, would have been available to authorized Westlaw subscribers as of the following times:
  - a. Business Wire article titled "BG-12 Psoriasis Study Meets Primary Endpoint; Oral Compound Also Being Studied for MS in Phase II Trial" was available on April 7, 2005 at 07:15:03 a.m. CT.
  - b. Business Wire article titled "Phase II Study of Oral Compound BG-12 Meets Primary Endpoint in Multiple Sclerosis" was available on January 9, 2006 at 07:49:24 a.m. CT.
  - c. Business Wire article titled "Oral Compound BG-12 Achieves Primary Endpoint in Phase II Study of Relapsing-Remitting Multiple Sclerosis; Treatment with BG-12 Led to Statistically Significant Reductions in MRI measures" was available on May 30, 2006 at 09:13:05 a.m. CT.

I affirm that the statements contained herein are known by me or believed by me to be true and correct.

7/3/2018



Signed by: U0067718

Sworn by Jennifer Rock, West Publishing Corporation, 610 Opperman Drive, Eagan, MN 55123

